02 September 2010

TERMSHEET
5 YEAR USD BRIC 40 RISK CONTROL INDEX LINKED NOTE

Exposure to the performance of the BRIC 40 Risk Control 10% Excess

Return Index
Overview

The return on this USD denominated Product is linked to the performance of the BRIC 40 Risk Control 10% Excess Return Index
(Bloomberg: SPTR10UE Index) (the “Underlying Index”), as described below.

The issuer of the Product will be Barclays Bank PLC (Aa3 / AA-). An investment in the Note will be subject to the credit risk of the
issuer and the actual and perceived creditworthiness of the issuer may affect the market value of the note over the term. If the issuer
of the Note fails to meet its obligations, you may get back less than is due to you or nothing at all.
Investors’ capital is repaid in full if the product is held to maturity. If sold prior to maturity, investors may get back less than initially
invested (see Secondary Market on page 3).
The Note may, under exceptional conditions, be subject to early redemptions or adjustments as described on page 4 (Adjustment,
early redemption, and determination of returns).

Index Description

The Index is calculated by Standard & Poor’s and is based on the performance of a portfolio of 40 leading securities, representing the
largest and most liquid companies in Brazil, Russia, India and China (BRIC). The total return – reflecting the price return and dividend
yield – of these equities is calculated, and the index’s exposure to the portfolio is set as a function of the volatility of the portfolio’s
price. In periods of high volatility, the exposure will be reduced; conversely in periods of low volatility the exposure will be increased.
The Index is an “excess return” index, meaning that it reflects the performance of this risk-adjusted exposure to the equities, minus
the return from USD money market rates (See Underlying Index for calculation methodology).

Product Description

At maturity there are two possible redemption scenarios:

 If the Underlying Index is above its initial level, investors will receive repayment of their initial investment plus a level of
participation in the positive performance of the Underlying Index. This participation rate will be set at launch and will not be lower
than 100%.
 If the Underlying Index is at or below its initial level, investors will receive 100% of their initial Investment at maturity.
 The return at maturity will be paid in USD.

This document is intended only as an overview of the features of the Product. Full details and the terms of the Product will be
contained in a Prospectus, and / or the Final Terms specific to the Product, copies of which are available on request.

Prospective investors should note that the contents of this document are indicative only and are subject to change prior to the Issue
Date. This Product may not be suitable for all recipients. This term sheet is not advice given to you. It does not take account of your
personal circumstances. You should ensure that you understand the characteristics of the Product in deciding whether to invest, and
if in doubt you should seek clarification from your Private Banker or other investment adviser. The securities described herein may not
be offered, sold or delivered to U.S. citizens, U.S. residents, or taxpayers in the United States of America
Please read important disclaimer at the end of this document

SN215-10 5 year USD BRIC 40 Risk Control Index Linked Note

Page 1
 02 September 2010

TERMSHEET – 5 YEAR USD BRIC 40 RISK CONTROL INDEX LINKED NOTE

Investment rationale
This Product may be suitable for investors who want to take exposure to the equity markets of Brazil, Russia, India and China, known
as BRIC, in a risk controlled way and who seek full repayment of capital at maturity.

Advantages Disadvantages
 The Product provides for full repayment of capital if held until  Investors do not receive any income from the Product.
maturity.
 Investors may get back less than they invested if they sell
 The Product provides uncapped participation to the positive before maturity.
performance of the Underlying Index with a participation
rate of 100%.  Because the exposure to the Underlying risk control index
can change during the term, the Index could underperform
 Compared to an outright investment in the S&P BRIC 40 the S&P BRIC 40 Index.
Index, the risk control index embeds a risk control
methodology which can reduce the potential risk to capital.  If the issuer of the Product fails to pay any sums due, you
may get back less than is due to you or nothing at all.

Return profile
The following section illustrates the potential performance of the Product at maturity assuming a participation rate of 100%, and is
not a prediction of market conditions.

Underlying Index
Product Value at
220% Performance at Product Performance
Maturity
200% Maturity
180% Index Product 30% 130.00% 30.00%
160%
20% 120.00% 20.00%
Product Value at Maturity

140%
15% 115.00% 15.00%
120%

100% 10% 110.00% 10.00%

80%
5% 105.00% 5.00%
60%

40%
0% 100.00% 0.00%
20% -10% 100.00% 0.00%
0%
-20% 100.00% 0.00%
%
0%

0%

0%

0%

0%

0%

%
%

0%

0%

0%

0%

0%
.0

.0

.0

.0

.0

.0

.0

.0

.0
.0

0.
0.

0.

0.

0.

0.

0.

0.

0.

0.

0.
10

20

30

40

50

60

70

80

90
00

-30% 100.00% 0.00%

10
-9

-8

-7

-6

-5

-4

-3

-2

-1
-1

Index Performance at Maturity

-40% 100.00% 0.00%

Indicative Issuance Details

Initial Valuation Date 04 October 2010

Trade Date [TBD]
Issue Date [04 October 2010]
Final Valuation Date 05 October 2015
Maturity Date 12 October 2015
Issuer Barclays Bank PLC (Aa3 / AA-)
Underlying Index S&P BRIC 40 Daily Risk Control 10% Excess Return (USD) Index (Bloomberg: SPTR10UE Index)

S&P Risk Control Methodology: The S&P Risk Control Index methodology controls the level of risk by varying exposure to an
underlying index based on systematic rules. By establishing a specific volatility target and managing the risk relative to the
target, this framework controls the level of risk. More specifically, the index consists of a position in an underlying index and a
cash position. If the risk level reaches a threshold that is too high, the cash level is increased to maintain the target volatility. If
the risk level gets too low, the index will employ leverage to maintain the targeted level of volatility. The exposure to the
underlying index is calculated by dividing the target risk level by the realized volatility of the underlying index. The target risk
level is set as a percentage and is typically 5%, 10%, 12%, or 15%.

Type Note

Please read important disclaimer at the end of this document

SN215-10 5 year USD BRIC 40 Risk Control Index Linked Note

Page 2
 02 September 2010

TERMSHEET – 5 YEAR USD BRIC 40 RISK CONTROL INDEX LINKED NOTE

Denomination USD 80,000 and integral multiples of USD 1,000 in excess thereof
Minimum Investment In the European Union, the minimum investment in this product is the higher of EUR 50,000 or the Denomination.
In Singapore, the minimum investment is the higher of the Denomination or SGD 200,000 if you are not a relevant person
(including but not limited to an "accredited investor") as defined in the Securities and Futures Act, Chapter 289 of Singapore.
In Hong Kong, the minimum investment is the higher of the Denomination or HKD 500,000 if you are not a "professional
investor" as defined in the Securities and Futures Ordinance (Cap. 571 of the laws of Hong Kong)

Different minimum amounts may apply in other jurisdictions.

Liquidity

Investment finance
If you need access to your funds during the term of the Product, the bank may be prepared to consider it as collateral.
As a guide, the Lending Value Percentage to be applied when calculating the collateral value of the Product is shown below, although
the exact value would depend on the context of the Product in your overall portfolio.
The provision of credit facilities is subject to credit approval and the completion of the relevant documentation.
Please note that using a credit facility to fund the purchase of the Product may significantly alter the risk profile of the investment on
an aggregate leveraged basis. The general effect of borrowing is to magnify gains and losses of the underlying investment. Where
the cost of that borrowing is greater than the return generated by the Product you may suffer a net loss in value on an aggregate
basis even if the Product has generated a positive return.
You must ensure that you fully understand the impact of borrowing on the investment and the consequences of failing to meet
interest and capital repayment obligations of the borrowing. This is explained in detail in the credit facility documentation.
Please discuss your objectives in detail with your private banker or investment adviser prior to making any decision to leverage.

Indicative lending value percentage

85%
Different rules apply under Monegasque law; clients of Barclays Private Bank in Monaco should ask their Private Banker for
further information.

Secondary market
A summary of the terms of the secondary market for the Product is shown below. These terms may change during the life of the
Product, and neither Barclays nor the Issuer are under any contractual obligation to provide a secondary market.
Please note that if you want to sell the Product before maturity you will only be able to do so through the secondary market arranged
by the Market Maker. For Products issued or arranged by Barclays Capital, the market maker will be a member of the Barclays Group.
The secondary market will only be available in normal market conditions, and in particular it may be difficult to sell the Product if
liquidity in the underlying market is limited.
There will, therefore, be a restricted market for transactions in the Product and it may be difficult to obtain reliable independent
information as to its value.
Where a Product provides full or partial capital protection, this will only apply at maturity, unless the terms of the Product specifically
state otherwise.
Where the return profile of a Product makes reference to a knock-in, credit event, barrier or other similar event, the secondary market
value of the Product may fall in anticipation of the event occurring.
In secondary market transactions, the current value of the Product will be calculated by the Market Maker based on the features of
the Product and prevailing market conditions. While movements in the underlying market factors will affect the value of the Product
during its term, it may also be affected by other factors such as changes in the level of interest rates, time to maturity, and other
factors as described under “General Risks” below.
It is impossible to predict whether the value of the Product will rise or fall, and its value at any time may be less than the sum
invested.

Please read important disclaimer at the end of this document

SN215-10 5 year USD BRIC 40 Risk Control Index Linked Note

Page 3
 02 September 2010

TERMSHEET – 5 YEAR USD BRIC 40 RISK CONTROL INDEX LINKED NOTE

Secondary market terms

Nature and frequency Daily, two-way, only under normal market conditions
Minimum transaction size USD 1,000 (Minimum bid size is equal to the Denomination)
Notice period None
Indicative spread Indicative Bid-offer spread of 1% under normal market conditions

Key risks

Risk Classification
Please note that the following Risk Classification is relevant ONLY to Clients of Barclays Wealth in Asia. This Product has been
classified as Risk Class 2 (please see below).

Class 1 Investments in this category carry a lower degree of risk and are expected to expose the investor to a low risk of loss of
capital invested. The price or value of the investment under normal market conditions should be relatively stable and there
should be a high degree of transparency in the pricing. In addition, this investment should benefit from high liquidity,
meaning that there is likely to be a good available market for selling the investment at any time if so desired.
Class 2 These investments carry a moderate degree of risk and expose the investor to a potential loss of the capital invested. The
market price or value of the investment under normal market conditions may be moderately volatile. In addition, there will be
lower liquidity, meaning that it may be less easy to dispose of the investment at a reasonable price at any time. Some
investments in this category might include leverage, which will generally increase the potential for losses as well as gains. No
guarantee or assurance can be given that profits will be achieved or that losses will not be incurred.
Class 3 Investments in this category carry a high degree of risk and may expose the investor to a possible total loss of the capital
invested. The market price or value of the investment, even under normal market conditions, could vary greatly and exhibit
sharp variations. In addition, liquidity may be low, meaning that it may be difficult or impossible to dispose of the investment
at a reasonable price at any time. Some investments in this category might include leverage, which will generally increase the
potential for losses as well as gains. No guarantee or assurance can be given that profits will be achieved or that substantial
losses will not be incurred. These investments are not suitable for investors with a risk profile that can be described as
"Income" or "Conservative".

The above descriptions are not a complete explanation of the risks involved. Prospective investors should read the offering
documentation and consult with their own advisers before deciding whether to invest.

Credit risk
Please note that, in addition to any market risk inherent to the Product, you will assume the full credit risk of the Issuer, and are reliant
on the Issuer and the Market Maker to fulfil their obligations in respect of the Product. You should consider the credit quality of the
Issuer before deciding to invest.

General risks
The value of the Product will be influenced by complex and interrelated political, economic, financial and other factors that affect the
capital markets generally.
Ownership of the Product exposes the Investor to many different risks, including (without limitation) interest rate, corporate, market,
foreign exchange, time value and/or political risks. Past performance does not guarantee or predict future performance.
Investors may also be exposed to foreign exchange risk, to the extent that they invest in Products denominated in a currency other
than their home currency or if the terms of the Product allow for conversion of principal.

Notes and Important Information

Adjustment, early redemption and determination of returns

The Issuer or its agent may be entitled to adjust the terms of the Product to cover unforeseen circumstances, such as changes to the
index, interest or currency rates or other factor underlying the Product or in response to a corporate event (such as merger,
insolvency or credit event) affecting any underlying asset on which the Product is based, or to cover any market disruption or change
in market conditions.

Please read important disclaimer at the end of this document

SN215-10 5 year USD BRIC 40 Risk Control Index Linked Note

Page 4
 02 September 2010

TERMSHEET – 5 YEAR USD BRIC 40 RISK CONTROL INDEX LINKED NOTE

It may be entitled to substitute different underlying indices, rates or shares and in some circumstances (such as a significant change
in taxation for the Issuer) it may be entitled to redeem or terminate the Products before maturity. The Issuer also has the right to
amend the dates on which market levels are observed or payments are made to reflect the business days applicable in the underlying
markets.
The Issuer or its agent will have discretion to calculate the returns on the Product, and in the absence of manifest error its decisions in
this respect will be final.
Full details are set out in the base prospectus, any supplemental prospectus and / or any Product terms, copies of which are available
on request.

Annualised Returns
Investors should note that, where coupons, interest rates or other payments are expressed as an annualised rate, the actual amounts
payable will be scaled to take account of the length of the relevant payment period. This scaling will be undertaken by the Calculation
Agent, in its sole discretion, and acting in accordance with prevailing market practice.

Withdrawal of issue
The Issuer may decide not to issue the Product before the Issue date.

Physical delivery
Where the product allows for physical delivery, the benefits due to be paid e.g. coupon or dividend will only be paid to clients once the
underlying has been received by the investor and once their details appear on the relevant register.

Conflicts
The Barclays Group is engaged in the full range of financial services activities, including but not limited to lending, dealing in
investments, corporate finance activities and securities issuance. These activities may from time to time affect the value of the
Product or the underlying instruments to which it is linked. Members of the Barclays Group and those associated with them may act
on both sides of the market. They will hold long positions and could hold short positions in instruments to which this Product is
referenced or instruments which are linked to them. This could affect the value, liquidity or price of those instruments and/or the
Product in a way which is adverse to the interests of an Investor. No member of the Barclays Group shall be under an obligation to
have regard to the consequences for Investors in conducting such activities. Members of the Barclays Group may also have
confidential information about the underlying instruments or which is otherwise relevant to the Products. They shall not be under
any obligation to disclose that information or to use it for the benefit of any Investor.

Calculation Agent
Unless otherwise specified above, the Calculation Agent will be a member of the Barclays Group and therefore potential conflicts of
interest may exist between the Calculation Agent and Investors, including with respect to certain determinations the Calculation
Agent may make in relation to the Products which could affect the amount payable in respect of them. These determinations are
generally required to be made in good faith and in a commercially reasonable manner, provided that the Calculation Agent assumes
no obligation to or relationship of agency or trust with any person other than the Issuer. The Calculation Agent is not acting as a
fiduciary of or advisor to any Investor in its capacity as Calculation Agent. In exercising its discretion, the Calculation Agent shall not
be required to take into account any person’s interest other than that of the Issuer. Investors’ interests could therefore be adversely
affected.

Credit ratings
One or more credit rating agencies may assign ratings to the Issuer or any underlying security or Reference Entity,. These ratings do
not reflect the potential impact of all risks related to structure, market and other factors that could affect the value or credit of any of
these. A credit rating is not a recommendation to buy, sell or hold any securities and may be revised or withdrawn by the rating
agency at any time, and in particular credit ratings may worsen over the term of the Product. No member of the Barclays Group
accepts any liability for any act or omission of a credit rating agency.

Charges
The terms of the Product may allow for the Issuer to pay a fee to Barclays Wealth. The amount of this fee will depend on market
conditions, but is not expected to exceed 1% of Principal for each year of the Product's term. The fee will be paid at trade date, and is

Please read important disclaimer at the end of this document

SN215-10 5 year USD BRIC 40 Risk Control Index Linked Note

Page 5
 02 September 2010

TERMSHEET – 5 YEAR USD BRIC 40 RISK CONTROL INDEX LINKED NOTE

not refundable in the event of early redemption or sale on the secondary market. Where the Issuer is member of the Barclays Group
the fee may be paid by intra-company transfer to the relevant division or group company.
Secondary market transactions may be subject to dealing or commission charges or a bid/offer spread. The Product may be subject
to custody charges in line with our normal tariff. Further details are available from your Private Banker.

Taxation
You have sole responsibility for the management of your tax and legal affairs including making any applicable filings and payments
and complying with any applicable laws and regulations. We have not and will not provide you with tax or legal advice and
recommend that you obtain your own independent tax and legal advice tailored to your individual circumstances.
The tax treatment of structured products can be complex, and the level and basis of taxation may alter during the term of any
product. Prospective investors should therefore obtain professional tax advice appropriate to their own circumstances
before investing.
Amounts due to be paid to investors are described on a gross basis, i.e. without calculating any tax liability. The Issuer shall make no
deduction for any tax, duty, or other charge unless required by law.
Returns from this investment may, in the case of resident/domiciled citizens of EU Countries, Dependencies, Territories and other
signatory states, be subject to either Information Exchange or Retention Tax under the European Savings Directive which was
incorporated by each EU Member State into local law, and implemented as “equivalent agreements” converted into local law in the
non-EU countries affected by ESD, with effect from 1 July 2005 (“ESD”).
Booking centre Potential ESD status for residents outside
respective booking centre
Jersey, Guernsey and IOM TBD
Monaco TBD
Switzerland TBD
Portugal TBD
Spain TBD
United Kingdom TBD

Valuations
Valuations will be issued periodically, and are also available on request from your Private Banker or other investment adviser.

Please read important disclaimer at the end of this document

SN215-10 5 year USD BRIC 40 Risk Control Index Linked Note

Page 6
 02 September 2010

TERMSHEET – 5 YEAR USD BRIC 40 RISK CONTROL INDEX LINKED NOTE

Important Information
This document has been issued and approved by Barclays Bank PLC. Although information in this document has been obtained from sources believed to be reliable, we do not
represent or warrant its accuracy, and such information may be incomplete or condensed. This document does not constitute a prospectus, offer, invitation or solicitation to
buy or sell securities and is not intended to provide the sole basis for any evaluation of the securities or any other instrument, which may be discussed in it. All estimates and
opinions included in this document constitute our judgement as of the date of the document and may be subject to change without notice.

This document is not a personal recommendation and you should consider whether you can rely upon any opinion or statement contained in this document without seeking
further advice tailored for your own circumstances. This document is confidential and is intended solely for the addressee(s). If you are not an addressee, or have received this
document in error, please notify the sender immediately, delete it from your system and do not copy, disclose or otherwise act upon any part of this e-mail or its attachments.
It may not be reproduced or disclosed (in whole or in part) to any other person without our prior written permission.

Where a version of this termsheet is issued in a language other than English, it is has been produced as a translation of the original English term sheet. In case of
inconsistencies, the English version shall prevail.

Law or regulation in certain countries may restrict the manner of distribution of this document and persons who come into possession of this document are required to inform
themselves of and observe such restrictions. We or our affiliates may have acted upon or have made use of material in this document prior to its publication. You should seek
advice concerning any impact this investment may have on your personal tax position from your own tax adviser.

Channel Islands Barclays Bank PLC is licensed by the Isle of Man Financial Supervision Commission for banking and investment business.
and Gibraltar Barclays Bank PLC is regulated by the Jersey Financial Services Commission.
Barclays Bank PLC is licensed under the Banking Supervision (Bailiwick of Guernsey) Law 1994, as amended, and the Protection of Investors (Bailiwick of
Guernsey) Law 1987, as amended.
Barclays Bank PLC. Authorised by the Gibraltar Financial Services Commission to conduct banking and investment in Gibraltar.
Dubai Barclays Wealth is the wealth management division of Barclays and operates through Barclays Bank PLC and its subsidiaries. Barclays Bank PLC is
registered in England and authorised and regulated by the Financial Services Authority. Registered number is 1026167 and its registered office is 1 Churchill
Place, London E14 5HP.
Barclays Bank PLC in the Dubai International Financial Centre (Registered No. 0060) is regulated by the Dubai Financial Services Authority. Barclays Bank
PLC-DIFC Branch, Wealth Management Division, may only undertake the financial services activities that fall within the scope of its existing DFSA licence.
Principal place of business in the DIFC: Barclays Wealth, Dubai International Financial Centre, The Gate Village Building No. 10, PO Box 506674, Dubai, UAE.
Barclays Bank PLC in the UAE is regulated by the Central Bank of the U.A.E. and is licensed to conduct business activities as a branch of a commercial bank
incorporated outside the UAE in Dubai (Licence No.: 13/1844/2008, Registered Office: Building No. 6, Burj Dubai Business Hub, Sheikh Zayed Rd, Dubai
City) and Abu Dhabi (Licence No.: 13/952/2008, Registered Office: Al Jazira Towers, Hamdan Street, PO Box 2734, Abu Dhabi).
Hong Kong IMPORTANT: If you are in doubt as to any aspect of this offer, you should consult a licensed securities dealer, bank manager,
solicitor, certified public accountant or other professional adviser.
Warning: The contents of this document have not been reviewed by any regulatory authority in Hong Kong. You are advised to exercise caution in
relation to the offer. If you are in any doubt about any of the contents of this document, you should obtain independent professional advice.

This is a structured product involving derivatives. The investment decision is yours, but you should not invest in
the product unless your private banker or investment adviser has explained to you that the product is suitable for
you having regard to your financial situation, investment experience and investment objectives
Where the product(s) described in this document take the form of shares or debentures: This document does not constitute an offer or invitation to the
public in Hong Kong to acquire securities in the company(ies) named in this document (“Securities”). Accordingly, unless permitted by the securities laws
of Hong Kong, (i) no person may issue or cause to be issued this document in Hong Kong, other than to persons who are "professional investors" as defined
in the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) and any rules made thereunder or in circumstances that do not constitute an
offer or sale of Securities to the public in Hong Kong for the purposes of the prospectus requirements of the Companies Ordinance (Cap. 32 of the Laws of
Hong Kong) or that do not constitute an offer to the public within the meaning of that Ordinance; and (ii) no person may issue or have in his or her
possession for the purposes of issue, this document, or any advertisement, invitation or document relating to the Securities, whether in Hong Kong or
elsewhere, that is directed at, or the contents of which are likely to be accessed or read by, the public in Hong Kong, other than with respect to the
Securities that are intended to be disposed of only to persons outside Hong Kong or only to "professional investors" as defined in the Securities and Futures
Ordinance (Cap. 571 of the Laws of Hong Kong) and any rules made thereunder.
Where the product(s) described in this document do not take the form of shares or debentures: This document does not constitute an offer or invitation
to the public in Hong Kong to acquire an interest in or subscribe for the product that is the subject matter of this document (“Product”). Accordingly, unless
permitted by the securities laws of Hong Kong, no person may issue or have in his or her possession for the purposes of issue, this document, or any
advertisement, invitation or document relating to the Product or the interest therein, whether in Hong Kong or elsewhere, that is directed at, or the contents
of which are likely to be accessed or read by, the public in Hong Kong, other than with respect to the Product or an interest therein that is intended to be
disposed of only to persons outside Hong Kong or only to "professional investors" as defined in the Securities and Futures Ordinance (Cap. 571 of the Laws
of Hong Kong) and any rules made thereunder.
Barclays Bank PLC is registered with the Securities and Futures Commission in Hong Kong (CE No. AAJ160) and is authorised and regulated by the
Hong Kong Monetary Authority. Main business address in Hong Kong: 42/F Citibank Tower, 3 Garden Road, Central, Hong Kong.
Monaco Barclays Bank PLC 31, avenue de la Costa, MC98000 Monaco, is a branch of Barclays Bank PLC , and is registered with the Monaco Chamber of Commerce
and Industry under no 68S01191. Registered VAT No FR 40 00002674 9.
Portugal Barclays Bank PLC activity in Portugal is supervised by Banco de Portugal (BoP) and Comissão de Mercado de Valores Mobiliários (CMVM).
Qatar Barclays Bank PLC in the Qatar Financial Centre (Registered No. 00018) is authorised by the Qatar Financial Centre Regulatory Authority. Barclays Bank
PLC-QFC Branch may only undertake the regulated activities that fall within the scope of its existing QFCRA licence. Principal place of business in Qatar:

Please read important disclaimer at the end of this document

SN215-10 5 year USD BRIC 40 Risk Control Index Linked Note

Page 7
 02 September 2010

TERMSHEET – 5 YEAR USD BRIC 40 RISK CONTROL INDEX LINKED NOTE

Qatar Financial Centre, Office 1002, 10th Floor, QFC Tower, Diplomatic Area, West Bay, PO Box 15891, Doha, Qatar.

This information has been distributed by Barclays Bank Plc. Related financial products or services are only available to Professional Clients as defined by the
DFSA, and Business Customers as defined by the QFCRA.
Singapore The contents of this document have not been reviewed by any regulatory authority in Singapore. You are advised to exercise caution in relation to the offer.
If you are in any doubt about any of the contents of this document, you should obtain independent professional advice
This document has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this document and any other document or
material in connection with the offer or sale, or invitation for subscription or purchase, of securities may not be circulated or distributed, nor may securities
be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i)
to an institutional investor under Section 274 of the Securities and Futures Act, Chapter 289 of Singapore (the “SFA”), (ii) to a relevant person pursuant to
Section 275(1), or any person pursuant to Section 275(1A), and in accordance with the conditions specified in Section 275 of the SFA, or (iii) otherwise
pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA.
Where securities are subscribed for or purchased under Section 275 by a relevant person, being:
(a) a corporation (not being an accredited investor (as defined in Section 4A of the SFA)) the sole business of which is to hold investments and the
entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or
(b) a trust (of which the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an
individual who is an accredited investor,
shares, debentures and units of shares and debentures of that corporation or the beneficiaries’ rights and interest (howsoever described) in that trust shall
not be transferred within six months after that corporation or that trust has acquired the securities pursuant to an offer made under Section 275 except:
(1) to an institutional investor (for corporations, under Section 274 of the SFA) or to a relevant person defined in Section 275(2) of the SFA, or to
any person pursuant to an offer that is made on terms such that such shares, debentures and units of shares and debentures of that corporation or such
rights and interest in that trust are acquired at a consideration of not less than S$200,000 (or its equivalent in a foreign currency) for each transaction,
whether such amount is to be paid for in cash or by exchange of securities or other assets, and further for corporations, in accordance with the conditions
specified in Section 275 of the SFA;
(2) where no consideration is or will be given for the transfer; or
(3) where the transfer is by operation of law.
Barclays Bank PLC is a licensed bank in Singapore and is regulated by the Monetary Authority of Singapore. Its members have limited liability.
Registered address: One Raffles Quay, Level 28, South Tower, Singapore 04858
Switzerland The prospectus, and/or the final terms specific to the product shall serve as and fulfil the requirements of a “Simplified Prospectus” in accordance with
Article 5 of the Swiss Federal Act on Collective Investment Schemes (CISA). The product may not be offered to the public in or from Switzerland and neither
this document nor any other offering materials relating to the product may be made available through a public offering in or from Switzerland. The product
may only be offered in or from Switzerland to qualified investors (as defined in CISA and its implementing ordinance).
This product is not a collective investment pursuant to Article 7 of CISA and thus does not require an authorisation from the Swiss Financial Market
Authority FINMA (FINMA). Consequently, Investors are not eligible for the specific investor protection under CISA and are exposed to issuer risk.
Barclays Bank (Suisse) SA is a Swiss Bank regulated and supervised by FINMA. Registered in Switzerland. Registered No. 1381/1986. Registered Office:
8/10 Rue d'Italie, CH1211, Geneva, Switzerland. Registered VAT No. 288 787.
United States The Products have not been and will not be registered under the U.S. Securities Act of 1933 (the "Securities Act"), or any state securities laws. The Products
may not be offered, sold, pledged, assigned, delivered or otherwise transferred or exercised or redeemed within the United States or to or for the account or
benefit of any U.S. Person. The Products are being offered and sold pursuant to the registration exemptions contained in Section 3(a)(2) of the Securities
Act and outside the United States to investors that are non-U.S. Persons in reliance on Regulation S under the Securities Act ("Regulation S"). Trading in
the Products has not been approved by the U.S. Securities and Exchange Commission, any state securities commission in the United States, the U.S.
Commodity Futures Trading Commission under the U.S. Commodity Exchange Act, as amended, or any U.S. federal or state banking authority.
Notes are subject to US tax law requirements and may not be offered, sold or delivered within the United States or its possessions, except in certain limited
circumstances as permitted by US tax regulations.

Barclays Wealth is the wealth management division of Barclays and operates through Barclays Bank PLC and its subsidiaries. Barclays Bank PLC is registered in England and
authorised and regulated by the Financial Services Authority. Registered number is 1026167 and its registered office is 1 Churchill Place, London E14 5HP.
© Barclays Bank PLC 2008. All rights reserved.

Rules and regulations for the protection of investors under the UK Financial Services and Markets Act 2000 will not apply to advice or services provided from offices located
outside the UK and investors conducting business through our non-UK offices will not be able to benefit from the provisions of the Financial Services Compensation Scheme in
relation to advice or services provided from that office.

Please read important disclaimer at the end of this document

SN215-10 5 year USD BRIC 40 Risk Control Index Linked Note

Page 8